AI-driven Approach to Treat Acute Coronary Syndrome: A Review on Integration of AlphaFold in Cardiovascular Genomics
Hira Mubeen, Madiha Khan, Irzam Kainat Rana, Sana Amir, Shiza Shahid, Muhammad Waseem Shoaib, Aawaiz IqbalIntroduction:
The constantly evolving nature of diseases has put humanity in a never- ending struggle for survival, adapting to each disease and fighting the silent battles with strength. Similarly, the complex cardiovascular system needs constant monitoring to prevent potential complications of inflammation, disrupted immune responses, blockages, heart attacks, angina, and other life-threatening conditions that end up triggering acute coronary syndrome (ACS). Its symptoms range from mild to severe and are typically challenging to identify, so early detection is crucial for successful treatment and prevention. To obtain a more precise and critical understanding of the potential genetic factors contributing to developing ACS, researchers use advanced and innovative approaches, like AlphaFold and artificial intelligence.
Methods:
Comprehensive knowledge about the integration of AlphaFold (AF) and artificial intelligence (AI) has been provided in this study, as it has completely changed how proteins interact by reliably predicting their three-dimensional structures from the order of their amino acids. Additionally, the role of immune cells in the progression of ACS has been discussed, along with therapeutic measures to treat ACS with next-generation sequencing (NGS).
Results:
The results have shown ischemia, plaque rupture, erosion, and thrombus formation to be the primary causes of ACS. These factors make the immune system's optimal function even more complicated, making it harder for researchers to find effective treatments for ACS patients.
Discussion:
The AlphaFold and AI have provided significant insights into the molecular mechanisms underlying ACS, highlighting the complex interplay between genetic factors and immune responses.
Conclusion:
This article has explored the potential of AlphaFold and AI in understanding the immunological mysteries of ACS, aiming to aid future therapeutic studies and reduce cardiovascular disease burden.